Immunome earnings were -$293.0M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest IMNM earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$80.2M, up 70.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IMNM reported annual earnings of -$293.0M, with 174.3% growth. The next IMNM earnings date is Mar 26, 2025.
On IMNM's earnings call on Invalid Date, Immunome (NASDAQ: IMNM) reported Q4 2024 earnings per share (EPS) of -$1.28, up 69.67% year over year. Total IMNM earnings for the quarter were -$80.25 million. In the same quarter last year, Immunome's earnings per share (EPS) was -$4.22.
The next IMNM earnings date is Invalid Date. Add IMNM to your watchlist to be reminded of Immunome's next earnings date.
Is Immunome profitable or losing money?
As of the last Immunome earnings report, Immunome is currently losing money. Immunome's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$292.96 million, a 174.29% increase year over year.
What was IMNM's earnings growth in the past year?
As of Immunome's earnings date in Invalid Date, Immunome's earnings has grown year over year. IMNM earnings in the past year totalled -$292.96 million.
What are Immunome's earnings expectations?
The current EPS estimate for Immunome's earnings report in Invalid Date is -$0.61.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.